The Absorption Problem
CBD is a lipophilic (fat-loving) molecule. This means it dissolves readily in fats and oils but poorly in water. The human digestive system, however, is primarily aqueous — the stomach, small intestine, and the fluids that facilitate absorption are all water-based.
When you take a conventional CBD oil sublingually or swallow a CBD capsule, the fat-soluble cannabinoid molecules must be emulsified by bile acids in the small intestine before they can be absorbed through the intestinal wall. This process is inefficient, variable, and highly dependent on what you've eaten. Studies on conventional CBD oil have found oral bioavailability ranging from 6% to 19% — meaning that between 81% and 94% of the CBD you consume never reaches your bloodstream.
This is not a minor inefficiency. It means that a 30mg dose of conventional CBD oil may deliver as little as 2-6mg of active compound to systemic circulation. The rest is metabolized in the gut or excreted.
What Micelles Are
A micelle is a spherical nanostructure formed by amphiphilic molecules — molecules that have both a water-loving (hydrophilic) head and a fat-loving (lipophilic) tail. When these molecules are placed in an aqueous environment at sufficient concentration, they spontaneously self-assemble into spheres with their lipophilic tails pointing inward and their hydrophilic heads pointing outward.
The interior of the micelle creates a lipophilic environment that can encapsulate fat-soluble compounds — including cannabinoids — while the hydrophilic exterior makes the entire structure water-compatible. The result is a cannabinoid molecule that behaves, from the perspective of the digestive system, like a water-soluble compound.
Micelle technology is not new. It has been used in pharmaceutical drug delivery for decades and is the basis for several approved injectable and oral drug formulations. Its application to hemp-derived cannabinoids represents a direct transfer of pharmaceutical-grade delivery technology to the supplement space.
How Micelle Encapsulation Improves Bioavailability
The bioavailability improvements from micelle encapsulation come through several mechanisms:
Bypassing bile acid emulsification. Conventional CBD oil requires bile acids to form emulsion droplets before absorption can occur. Micelle-encapsulated CBD arrives at the intestinal wall already in a water-compatible form, bypassing this rate-limiting step.
Reduced particle size. Micelles are typically 10-100 nanometers in diameter — far smaller than the emulsion droplets formed by conventional oil digestion. Smaller particle size dramatically increases the surface area available for absorption and allows micelles to penetrate the mucus layer of the intestinal wall more effectively.
Lymphatic absorption pathway. Micelle-encapsulated cannabinoids can be absorbed directly into the lymphatic system through intestinal lacteals, partially bypassing the hepatic first-pass metabolism that degrades a significant portion of orally administered lipophilic compounds before they reach systemic circulation.
Reduced food dependency. Conventional CBD oil bioavailability is significantly higher when taken with a high-fat meal — because dietary fat stimulates bile acid secretion and facilitates emulsification. Micelle-encapsulated CBD achieves high bioavailability regardless of food intake, making dosing more predictable and consistent.
The Research on Micelle-Enhanced Cannabinoid Bioavailability
Several studies have quantified the bioavailability improvements from lipid nanoparticle and micelle delivery systems for cannabinoids:
A 2019 study published in Cannabis and Cannabinoid Research found that a self-emulsifying drug delivery system (SEDDS) — a precursor technology to micelle encapsulation — increased CBD bioavailability by approximately 4-fold compared to conventional oil in a human crossover study.
A 2020 study in the European Journal of Pharmaceutics and Biopharmaceutics found that lipid nanoparticle encapsulation of CBD increased peak plasma concentration by 6-fold and area under the curve (a measure of total exposure) by 4-fold compared to unencapsulated CBD in an animal model.
The most advanced micelle formulations — using pharmaceutical-grade amphiphilic polymers and optimized particle size — have demonstrated bioavailability improvements of up to 16-fold in comparative studies. This is the technology basis for our "up to 16× more bioavailable" claim, which is derived from published comparative research on micelle-encapsulated versus conventional oil-based cannabinoid delivery.
What This Means for Dosing
The practical implication of improved bioavailability is significant: you need less active compound to achieve the same systemic exposure. A 10mg dose of micelle-encapsulated CBD may deliver more active compound to your tissues than a 50mg dose of conventional CBD oil.
This has implications for both efficacy and cost. Products with superior bioavailability technology can be formulated at lower nominal doses while delivering equivalent or superior therapeutic exposure — which means lower per-serving costs for consumers who understand what they're buying.
It also means that if you've tried CBD products without results, bioavailability is very likely the overlooked variable. The dose on the label is not the dose that reaches your cells.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Learn about our delivery technology →